vs

Side-by-side financial comparison of MADRIGAL PHARMACEUTICALS, INC. (MDGL) and SL GREEN REALTY CORP (SLG). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $276.5M, roughly 1.2× SL GREEN REALTY CORP). MADRIGAL PHARMACEUTICALS, INC. runs the higher net margin — -18.2% vs -36.5%, a 18.2% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 12.4%).

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

SL Green Realty Corp. is a real estate investment trust that primarily invests in office buildings and shopping centers in New York City. As of December 31, 2024, the company owned interests in 39 properties comprising 25,297,353 square feet, primarily in Manhattan. It has been referred to as "New York City’s largest office landlord".

MDGL vs SLG — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.2× larger
MDGL
$321.1M
$276.5M
SLG
Growing faster (revenue YoY)
MDGL
MDGL
+198.3% gap
MDGL
210.8%
12.4%
SLG
Higher net margin
MDGL
MDGL
18.2% more per $
MDGL
-18.2%
-36.5%
SLG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MDGL
MDGL
SLG
SLG
Revenue
$321.1M
$276.5M
Net Profit
$-58.6M
$-100.8M
Gross Margin
Operating Margin
-18.6%
64.2%
Net Margin
-18.2%
-36.5%
Revenue YoY
210.8%
12.4%
Net Profit YoY
1.4%
-870.0%
EPS (diluted)
$-2.55
$-1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDGL
MDGL
SLG
SLG
Q4 25
$321.1M
$276.5M
Q3 25
$287.3M
$244.8M
Q2 25
$212.8M
$241.9M
Q1 25
$137.3M
$239.8M
Q4 24
$103.3M
$245.9M
Q3 24
$62.2M
$229.7M
Q2 24
$222.8M
Q1 24
$0
$187.9M
Net Profit
MDGL
MDGL
SLG
SLG
Q4 25
$-58.6M
$-100.8M
Q3 25
$-114.2M
$28.6M
Q2 25
$-42.3M
$-7.4M
Q1 25
$-73.2M
$-17.3M
Q4 24
$-59.4M
$19.1M
Q3 24
$-107.0M
$-9.5M
Q2 24
$1.6M
Q1 24
$-147.5M
$16.9M
Gross Margin
MDGL
MDGL
SLG
SLG
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
MDGL
MDGL
SLG
SLG
Q4 25
-18.6%
64.2%
Q3 25
-39.7%
85.5%
Q2 25
-22.2%
53.4%
Q1 25
-57.8%
56.7%
Q4 24
-64.8%
59.8%
Q3 24
-187.1%
65.1%
Q2 24
79.2%
Q1 24
Net Margin
MDGL
MDGL
SLG
SLG
Q4 25
-18.2%
-36.5%
Q3 25
-39.8%
11.7%
Q2 25
-19.9%
-3.0%
Q1 25
-53.4%
-7.2%
Q4 24
-57.5%
7.8%
Q3 24
-172.0%
-4.2%
Q2 24
0.7%
Q1 24
9.0%
EPS (diluted)
MDGL
MDGL
SLG
SLG
Q4 25
$-2.55
$-1.49
Q3 25
$-5.08
$0.34
Q2 25
$-1.90
$-0.16
Q1 25
$-3.32
$-0.30
Q4 24
$-2.50
$0.13
Q3 24
$-4.92
$-0.21
Q2 24
$-0.04
Q1 24
$-7.38
$0.20

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDGL
MDGL
SLG
SLG
Cash + ST InvestmentsLiquidity on hand
$198.7M
$155.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$602.7M
$3.7B
Total Assets
$1.3B
$11.1B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDGL
MDGL
SLG
SLG
Q4 25
$198.7M
$155.7M
Q3 25
$295.7M
$187.0M
Q2 25
$186.2M
$182.9M
Q1 25
$183.6M
$180.1M
Q4 24
$100.0M
$184.3M
Q3 24
$232.7M
$188.2M
Q2 24
$199.5M
Q1 24
$622.5M
$196.0M
Total Debt
MDGL
MDGL
SLG
SLG
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
MDGL
MDGL
SLG
SLG
Q4 25
$602.7M
$3.7B
Q3 25
$625.7M
$3.8B
Q2 25
$696.0M
$3.8B
Q1 25
$710.6M
$3.8B
Q4 24
$754.4M
$4.0B
Q3 24
$777.2M
$3.6B
Q2 24
$3.7B
Q1 24
$850.8M
$3.7B
Total Assets
MDGL
MDGL
SLG
SLG
Q4 25
$1.3B
$11.1B
Q3 25
$1.4B
$11.1B
Q2 25
$1.0B
$11.3B
Q1 25
$996.6M
$11.4B
Q4 24
$1.0B
$10.5B
Q3 24
$1.1B
$10.2B
Q2 24
$9.5B
Q1 24
$1.1B
$9.8B
Debt / Equity
MDGL
MDGL
SLG
SLG
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDGL
MDGL
SLG
SLG
Operating Cash FlowLast quarter
$-133.5M
$82.9M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDGL
MDGL
SLG
SLG
Q4 25
$-133.5M
$82.9M
Q3 25
$79.8M
$-6.8M
Q2 25
$-47.1M
$54.5M
Q1 25
$-88.9M
$6.7M
Q4 24
$-104.5M
$129.6M
Q3 24
$-67.0M
$16.7M
Q2 24
$79.4M
Q1 24
$-149.2M
$-24.7M
Free Cash Flow
MDGL
MDGL
SLG
SLG
Q4 25
$-133.8M
Q3 25
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
Q1 24
$-149.5M
FCF Margin
MDGL
MDGL
SLG
SLG
Q4 25
-41.7%
Q3 25
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Q1 24
Capex Intensity
MDGL
MDGL
SLG
SLG
Q4 25
0.1%
Q3 25
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Q1 24
Cash Conversion
MDGL
MDGL
SLG
SLG
Q4 25
Q3 25
-0.24×
Q2 25
Q1 25
Q4 24
6.77×
Q3 24
Q2 24
50.33×
Q1 24
-1.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

SLG
SLG

Real Estate Segment$223.1M81%
Other$35.9M13%
Debt And Preferred Equity Segment$17.4M6%

Related Comparisons